Warren Slams Inhaler Manufacturer GSK for its Billion Dollar Drug Price-Gouging Scheme, Harming Millions of Children
December 09, 2024
December 09, 2024
WASHINGTON, Dec. 9 -- Sen. Elizabeth Warren, D-Massachusetts, issued the following news release:
Senator Elizabeth Warren (D-Mass.) sent GlaxoSmithKline (GSK) a follow-up letter on its decision to discontinue Flovent HFA, the go-to inhaler for children, and replace it with an authorized generic version of the drug. This comes after new research from John Hopkins University revealed that GSK's pricing scheme was costing patients, taxpayers, and state Medicaid programs.
I . . .
Senator Elizabeth Warren (D-Mass.) sent GlaxoSmithKline (GSK) a follow-up letter on its decision to discontinue Flovent HFA, the go-to inhaler for children, and replace it with an authorized generic version of the drug. This comes after new research from John Hopkins University revealed that GSK's pricing scheme was costing patients, taxpayers, and state Medicaid programs.
I . . .